...
首页> 外文期刊>International Urology and Nephrology >The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
【24h】

The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.

机译:上皮性T1期膀胱尿路上皮癌中E-cadherin的表达与肿瘤复发和进展的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate the relationship between the expression of E-cadherin (E-CD) and tumor recurrence and progression in patients with high-grade stage T1 urothelial carcinoma of bladder. METHODS: Fifty-two patients who had primary high-grade stage T1 urothelial carcinoma were enrolled to the study. The pathologic specimens of patients were evaluated and staged as T1a and T1b according to muscularis mucosae involvement by the tumor. The immunohistochemical demonstration of E-CD was accomplished by using immunoperoxidase method and all the specimens were examined under light microscope for E-CD level. RESULTS: The mean age of the patients was 64.0 +/- 7.7 (range 36-81) years. The mean follow-up period was 56.4 +/- 19.4 (range 14-84) months. Among 52 patients, 27 (52%) of them were stage T1b and 25 (48%) were T1a tumors. The recurrence rates for T1a and T1b groups were 52% (n = 13) and 92.6% (n = 25), respectively (P < 0.05). The expression of E-CD was homogenous in 52% of pT1a and 14.8% of T1b tumors(P < 0.05). In T1a group with recurrence, homogeneous E-CD staining ratio was 30.7% (n 4/13), but it was 75% (n In T1b group with recurrence, the homogenous expression of E-CD was 12% (n = 3/25) and the expression of E-CD was heterogenous in 88% (n = 22/25) of them (P < 0.05). In T1a group, progression of the disease was detected in 28% (n = 7/25) of the patients, but disease progression was seen in 55.5% (n = 15/27) of T1b group patients (P < 0.05). In T1a group with progression, heterogeneous E-CD staining ratio was 85.7% (n = 6/7), but it was 80% (n = 12/15) in T1b patients with progression. The effects of tumor number, tumor size and carcinoma in situ presence on recurrence were evaluated within each group. It was determined that parameters such as tumor number and tumor size had no significant effect on recurrence of the groups. The mean survival rates were statistically different between the groups. On multivariate analysis only E-cadherin expression (P = 0.012, odds ratio 6.291, 95% confidence intervalfor odds ratio 1.303-4.72) and tumor stage (P = 0.003, odds ratio 11.58, 95% confidence interval for odds ratio 2.446-8.542) remained independently significant as predictors of recurrence. CONCLUSION: E-CD expression was decreased in pathologic specimens of bladder tumor patients with muscularis mucosae involvement and this condition correlated well with tumor recurrence.
机译:目的:探讨E-钙黏着蛋白(E-CDherin,E-CDherin,E-CDherin,E-CDherin,E-CDherin,E-cadherin,E-CD)的表达与T1期膀胱尿路上皮癌的关系。方法:52例原发性高级别T1尿路上皮癌患者被纳入研究。评估患者的病理学标本,并根据肿瘤对肌层粘膜的侵袭将其分为T1a和T1b。 E-CD的免疫组织化学证明是通过免疫过氧化物酶法完成的,所有标本在光学显微镜下检查E-CD的水平。结果:患者的平均年龄为64.0 +/- 7.7岁(范围36-81)。平均随访期为56.4 +/- 19.4个月(范围14-84)。在52例患者中,其中27例(52%)为T1b期,而25例(48%)为T1a肿瘤。 T1a和T1b组的复发率分别为52%(n = 13)和92.6%(n = 25)(P <0.05)。 E-CD在52%的pT1a和14.8%的T1b肿瘤中表达均一(P <0.05)。在复发的T1a组中,均匀的E-CD染色率为30.7%(n 4/13),但在平均复发率中为75%(n在复发的T1b组中,E-CD的均匀表达为12%(n = 3 / 25),其中E-CD的表达在88%(n = 22/25)中是异源的(P <0.05)。在T1a组中,在28%(n = 7/25)的患者中发现了疾病进展。 T1b组患者中疾病进展为55.5%(n = 15/27)(P <0.05)。进展的T1a组中,异种E-CD染色率为85.7%(n = 6/7) ,但在进展期T1b患者中为80%(n = 12/15),评估各组中肿瘤数目,肿瘤大小和原位癌的存在对复发的影响,确定肿瘤数目和肿瘤的大小对各组的复发无显着影响,各组的平均生存率差异有统计学意义;在多变量分析中,仅E-cadherin表达(P = 0.012,比值6.291,95%置信度)。几率比值1.303-4.72)和肿瘤分期(P = 0.003,比值比11.58,比值比2.446-8.542的95%置信区间)仍然是复发的预测指标。结论:膀胱粘膜肌层受累的膀胱肿瘤患者的病理标本中E-CD的表达降低,这种情况与肿瘤的复发相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号